Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2025 Earnings Call Transcript February 23, 2026Axsome Therapeutics, Inc. misses on earnings expectations.
Axsome Therapeutics Inc. (AXSM)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 1,150,000 | $210,036,000 | +28% | 3.74% |
| 2. | D E Shaw D. E. Shaw | 549,113 | $100,289,998 | +86% | 0.05% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 367,578 | $67,134,446 | -18% | 0.1% |
| 4. | Hood River Capital Management David Swank | 366,176 | $66,878,385 | +2% | 0.73% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 320,568 | $58,548,541 | -16% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $127.40 | 488 | $62,171.20 | 48,212 | 2025-09-08 | Filing | |
| $127.30 | 287 | $36,535.10 | 47,724 | 2025-09-08 | Filing | |
| $127.20 | 800 | $101,760.00 | 47,437 | 2025-09-08 | Filing | |
| $37.30 | 3,950 | $147,350.01 | 120,756 | 2021-11-19 | Filing | |
| $35.20 | 142 | $4,998.40 | 142 | 2021-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $185.60 | 32,410 | $6,015,296.00 | 7,229 | 2026-02-02 | Filing | |
| $187.92 | 12,000 | $2,255,040.00 | 42,588 | 2026-01-22 | Filing | |
| $184.44 | 7,500 | $1,383,300.00 | 0 | 2026-01-21 | Filing | |
| $170.38 | 31,261 | $5,326,249.18 | 7,229 | 2026-01-07 | Filing | |
| $172.33 | 29,450 | $5,075,118.50 | 7,229 | 2026-01-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,164,818 | $760,662,360 | 0.01% | |
| 2. | 3,913,543 | $714,769,493 | 0.01% | |
| 3. | 1,273,494 | $232,590,944 | 0.04% | |
| 4. | 1,221,656 | $223,123,252 | 0.04% | |
| 5. | 1,181,622 | $215,811,444 | 0.01% |
News See All
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the mid-cap stocks to buy according to top investors. On January 20, H.C. Wainwright boosted its price target for Axsome Therapeutics Inc.
Top Investors' Stock Portfolio: 10 Mid-cap Stocks To Buy
The Fed's change from higher interest rates to rate cuts has caused what Amy Y. Zhang, portfolio manager of the Alger Mid Cap 40 ETF, refers to as a "headwind to tailwind" shift in mid-cap companies.
Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
Axsome Therapeutics Inc. (NASDAQ:AXSM) is one of the best mid-cap growth stocks to buy right now.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2025 Earnings Call Transcript November 3, 2025Axsome Therapeutics, Inc. misses on earnings expectations.
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best biotech stocks to buy. Following a recent discussion with the senior management at Axsome Therapeutics Inc.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
H.C. Wainwright Reaffirms Buy on Axsome (AXSM) Following Generic Challenge to Portfolio
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best mid-cap stocks with huge upside potential. H.C. Wainwright reaffirmed its Buy rating and $180 price target for Axsome Therapeutics Inc.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Commerce Department said on August 29 that core inflation, which does not include food and energy expenses, stood at a 2.9% seasonally adjusted annual rate based on the personal consumption expenditures...
Hedge Fund Resource Center